Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $66.00

Definium Therapeutics (NASDAQ:DFTX) had its target price lifted by Needham & Company LLC from $50.00 to $66.00 in a research report report published on Wednesday, MarketBeat.com reports. The firm currently has a buy rating on the stock.

Several other research firms have also commented on DFTX. Canaccord Genuity Group set a $58.00 price target on Definium Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Piper Sandler reiterated an “overweight” rating and issued a $75.00 target price (up from $73.00) on shares of Definium Therapeutics in a research note on Friday, August 7th. Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Oppenheimer reissued an “outperform” rating and set a $70.00 price target on shares of Definium Therapeutics in a research report on Wednesday. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $62.14.

Definium Therapeutics Stock Performance

NASDAQ DFTX opened at $42.63 on Wednesday. The stock has a market capitalization of $5.73 billion, a PE ratio of -12.43 and a beta of 2.23. The business has a 50 day simple moving average of $39.83 and a two-hundred day simple moving average of $26.82. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95. Definium Therapeutics has a 1-year low of $8.70 and a 1-year high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, research analysts predict that Definium Therapeutics will post -2.81 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Brandi Roberts sold 3,013 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the sale, the chief financial officer directly owned 209,487 shares of the company’s stock, valued at $9,433,199.61. This trade represents a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Robert Barrow sold 29,208 shares of Definium Therapeutics stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the transaction, the chief executive officer directly owned 1,098,246 shares of the company’s stock, valued at approximately $49,454,017.38. This trade represents a 2.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 48,096 shares of company stock worth $2,165,763. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of DFTX. Royal Bank of Canada boosted its stake in shares of Definium Therapeutics by 10.4% during the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock worth $382,000 after acquiring an additional 6,148 shares in the last quarter. Creative Planning increased its stake in shares of Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after purchasing an additional 1,655 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Definium Therapeutics by 5.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after purchasing an additional 2,342 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Definium Therapeutics by 6.3% in the 2nd quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock valued at $748,000 after purchasing an additional 6,839 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares during the period. Institutional investors and hedge funds own 27.91% of the company’s stock.

Key Headlines Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported that its Phase 3 VOYAGE study of DT120 ODT in generalized anxiety disorder achieved its primary goals. The treatment produced a 5.4-point improvement on the HAM-A anxiety scale versus placebo, strengthening the case for DT120’s potential efficacy and supporting future regulatory and commercial plans. Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo
• Positive Sentiment: The positive clinical readout has increased confidence in additional DT120 trials and potentially supports the drug’s use across more than one indication. Investors are also watching for a further catalyst expected in September 2026. Definium Therapeutics Hits Phase 3 GAD Goals For DT120 ODT
• Positive Sentiment: Analysts raised their targets following the data: JonesTrading increased its target to $90 from $74 and maintained a Buy rating; Robert W. Baird raised its target to $75 from $57; Wells Fargo lifted its target to $72 from $68; and RBC raised its target to $66 from $57 while assigning an Outperform rating. These revisions indicate substantial perceived upside, although targets are not guarantees. Analyst price-target updates
• Positive Sentiment: Needham reportedly expects DFTX shares to rise, while recent analyst commentary broadly reflects optimism about DT120’s development prospects. Needham analyst outlook
• Neutral Sentiment: Near-term trading may remain volatile as investors assess the Phase 3 results, upcoming milestones, and expectations for third-quarter earnings. HC Wainwright Q3 earnings estimate
• Negative Sentiment: DFTX remains an unprofitable biotechnology company, and its latest reported quarter missed consensus EPS estimates. The stock’s large recent rally and elevated volatility could also encourage profit-taking despite the favorable trial news.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.